Ekso GT Named a Finalist in Fast Company’s 2017 World Changing Ideas Awards
RICHMOND, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced that the EksoGT has been named as a finalist in Fast Company’s 2017 World Changing Ideas Awards. In its premier year, the awards garnered more than 1,200 entries, and the EksoGT wearable exoskeleton was chosen from more than 250 entries as a finalist in the Health category of this award.
“We are honored to be selected as a finalist and would like to thank Fast Company for recongizing Ekso Bionics,” commented Thomas Looby, president and chief executive officer of Ekso Bionics. “Our company was built on innovation and with the ultimate goal of changing lives around the world with our proprietary exoskeleton technologies.”
The EksoGT exoskeleton enables individuals who are disabled due to stroke or spinal cord injury to stand up and walk with a full weight bearing, reciprocal gait. Designed for the rehabilitation setting, the EksoGT provides adaptive amounts of power to either side of the patient’s body, allowing mobility to patients earlier in their recovery than current standards of care in rehabilitation. Physicians and physical therapists use this advanced therapeutic option to help patients get back on their feet, supporting re-learning of correct step patterns. Utilized by over 130 rehabilitation centers around the world, the Ekso GT has helped patients take more than 70 million steps, while supporting patients’ hopes of early mobility and independence.
“Fast Company has always insisted that being a force for good has to be a key element for any business,” says Fast Company editor and managing director Robert Safian. “Companies like Ekso Bionics, recognized for its World Changing Idea, show how organizations around the world are embracing the ideals of creativity and innovation to create enormous impact.”
The 2017 World Changing Ideas Awards finalists will be highlighted in Fast Company’s April issue of their monthly publication, which hits newsstands on March 27th.
To learn more about the EksoGT, visit www.eksobionics.com.
About Fast Company
Fast Company is a progressive business media brand, with an editorial focus on innovation in technology, leadership, world changing ideas, and design. Fast Company chronicles how changing companies create and compete, highlighting new business practices, and showcasing the teams and individuals who are inventing the future and reinventing business.
World Changing Ideas is one of Fast Company’s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose winners and finalists based on feasibility and the potential for impact. With a goal of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start work on solving the problems that affect us all.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso GT™
Ekso GT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 70 million steps in over 130 rehabilitation institutions around the world.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Carrie Yamond 917-371-2320 email@example.com Investor Contact: Debbie Kaster 415-937-5403 firstname.lastname@example.org
Released March 21, 2017